Poseida Therapeutics Sees Unusually High Options Volume (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the recipient of some unusual options trading on Tuesday. Investors purchased 5,174 put options on the stock. This represents an increase of 3,372% compared to the typical volume of 149 put options.

Poseida Therapeutics Price Performance

Shares of NASDAQ PSTX opened at $9.38 on Wednesday. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $9.41. The business has a 50 day moving average price of $2.90 and a two-hundred day moving average price of $2.97. The firm has a market cap of $914.17 million, a PE ratio of -14.89 and a beta of 0.54.

Institutional Trading of Poseida Therapeutics

A number of hedge funds have recently made changes to their positions in PSTX. The Manufacturers Life Insurance Company increased its position in shares of Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after purchasing an additional 3,552 shares during the last quarter. Rhumbline Advisers increased its holdings in Poseida Therapeutics by 4.2% in the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock valued at $283,000 after buying an additional 3,875 shares during the last quarter. American Century Companies Inc. raised its stake in Poseida Therapeutics by 5.9% during the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock valued at $264,000 after buying an additional 5,023 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Poseida Therapeutics by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after acquiring an additional 9,672 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of Poseida Therapeutics in the 1st quarter valued at approximately $33,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Analysts Set New Price Targets

PSTX has been the topic of several recent research reports. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday. HC Wainwright restated a “neutral” rating and issued a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.